Monte Nido logo
Treatment
What we treat
What we treatAnorexia NervosaAtypical AnorexiaBulimia NervosaBinge Eating
See all
Who we serve
Who we serveAdolescentsAll gendersFamilies and loved onesAthletes
See more
Programs
Our programsVirtual treatmentDay treatmentResidential treatmentInpatient treatment
Admissions
AdmissionsInsurance CheckerFinancial considerationsFAQ
APPROACH
Our approachTherapeutic philosophyNutrition

Do I have an eating disorder?

This 2-minute quiz can help you see if you or your loved one might have an eating disorder.

Take the screening assessment
Locations
ArizonaArizona
CaliforniaCalifornia
ColoradoColorado
ConnecticutConnecticut
FloridaFlorida
GeorgiaGeorgia
IdahoIdaho
IllinoisIllinois
MaineMaine
MarylandMaryland
MassachusettsMassachusetts
MissouriMissouri
MontanaMontana
NevadaNevada
New HampshireNew Hampshire
New JerseyNew Jersey
New YorkNew York
North CarolinaNorth Carolina
OhioOhio
OregonOregon
PennsylvaniaPennsylvania
Rhode IslandRhode Island
South CarolinaSouth Carolina
TennesseeTennessee
TexasTexas
UtahUtah
VermontVermont
VirginiaVirginia
WashingtonWashington
VirtualVirtual
a map of the united states of the united states

Discover the Nearest Location

Get matched with our nearest location by sharing a bit about yourself.

Find a locationSeek virtual care
For You
For loved ones
Arrow Right
For clients & alumni
Arrow Right
Caring for loved onesVirtual support groupsResources for loved ones
For alumni
Post-treatment supportVirtual support groups for alumniResources
Documents
Request a medical record

Latest content for loved ones

See all
May 15, 2025
Causes of Body Image Issues in Adolescence
May 12, 2025
6 Facts About Binge Eating Disorder You Might Not Have Known
May 9, 2025
What to Do If You Think Your Child Has Bulimia Nervosa

Latest content for you

See all
May 19, 2025
Eating Disorders and Co-Occurring Mental Health Conditions
May 12, 2025
6 Facts About Binge Eating Disorder You Might Not Have Known
March 17, 2025
How a Dietitian Can Help with Eating Disorders
Placeholder
For Providers
Referrals 101
Outpatient ProvidersFacilities & Hospitals
Continuing educationMeet our Outreach Team
Refer now: Outpatient Providers
Refer now: Facilities & Hospitals

Latest content for providers

See all
May 14, 2025
Unpacking Asian American Eating Disorders and Cultural Influences
April 9, 2025
What is ARFID? Understanding Diagnosis and Treatment
March 12, 2025
Attention Needed: Navigating ADHD and Eating Disorders
About Us
About us
What Monte Nido isOur latest outcomes reportTrusted outcomesLeadershipAdvocacy
Reference
TestimonialsOur work in the newsBlog
Admissions
AdmissionsInsurance CheckerFinancial considerationsFAQ
Join
Careers
Reach out to us
888-228-1253
Reach out to us
Home
Blog
Exploring the GLP-1 Dilemma: Weight Loss vs. Eating Disorder Risks
Home
Blog
Exploring the GLP-1 Dilemma: Weight Loss vs. Eating Disorder Risks
For providers

Exploring the GLP-1 Dilemma: Weight Loss vs. Eating Disorder Risks

January 27, 2025

6 min read

Joel Jahraus

On January 15th, 2025, Monte Nido Vice President of Medical Services, Joel Jahraus MD, CEDS, FED, FIAEDP hosted “The GLP-1 Dilemma: Exploring the Intersection of Weight Loss Success and Eating Disorder Risks,” an informative webinar discussing a topic that is at the forefront of many conversations in the healthcare field.  

The Status of GLP-1s and Their Unique Characteristics

  • People with and without diabetes are rushing to obtain this class of medications for weight loss, creating shortages
  • GLP-1s can cause additive effects to the medical state of those with eating disorders, including appetite suppression, weight loss, nausea and vomiting, etc.
  • Currently over 120 weight loss medications in development
  • GLP-1 participates in the regulation of blood sugar (glucose)
  • GLP-1 also ensures the bata cell insulin stores are replenished to prevent exhaustion during secretion
  • Effective in short term weight loss – the STEP 2 study of semaglutide with life-style changes showed 33.7 lbs of weight loss with the medication vs. 5.7 lbs without it at 68 weeks. Eventually, the weight plateaued and actually increased thereafter, which mitigated the overall weight loss

Weight Stigma, Weight Loss Medications, and Eating Disorders

  • GLP-1s intensify discussions about weight loss that cause many living in larger bodies to express a sense of hopelessness in “fat-focused” conversations
  • It is time to consider how to handle significant numbers of clients coming into eating disorder treatment programs on GLP-1s
  • Clinicians need to consider what clients have been through with societal impact and weight stigma when making the ultimate decision regarding these medications. Consider their eating disorder diagnosis and risks of continuing these medications. Ultimately, the risks may be too substantial.  
  • There are no current FDA approved medications to treat BED specifically  
  • As long as the client meets reasonable criteria for a GLP-1 prescription, it is the client’s choice as to whether they want to continue to use this medication while in BED treatment. Clients should also be aware of the potential risks of engaging in treatment with these medications.
  • Weight loss medications are dangerous for children as they are in a vulnerable period for the development of low self-esteem and eating disorders  

Balancing GLP-1s for Medical Use and Social Impacts

In his presentation, Dr. Joel Jahraus explored the role of weight loss medications in society and in eating disorder treatment as the integration of these medications is now a reality within the eating disorder field. Understanding the medical impacts of GLP-1s and navigating their usage in a weight stigma-based society is integral to considering this timely dilemma.

‍

Citations:  

Cooper DM, Rothstein MA,Amin A, Hirsch JD, and Cooper E. Unintended consequences of glucagon-like peptide-1

receptor agonists medications in children and adolescents: A call to action. Journal of Clinical and Translational Science 7: e184, 1–4. doi: 10.1017/cts.2023.612

White GE, Shu I, Rometo D, Arnold J, Korytkowski M, Luo J. Real-world weight-loss effectiveness of glucagon-like peptide-1 agonists among patients with type 2 diabetes: A retrospective cohort study. Obesity (Silver Spring). 2023 Feb;31(2):537-544.

Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I; STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021 Mar 13;397(10278):971-984. doi: 10.1016/S0140-6736(21)00213-0. Epub 2021 Mar 2. PMID: 33667417.

‍

Most recent articles

illustration of people profiles
For you
May 19, 2025
7 min read

Eating Disorders and Co-Occurring Mental Health Conditions

Read more
Young girl with headphones looking mirror taking a selfie
For loved ones
May 15, 2025
8 min read

Causes of Body Image Issues in Adolescence

Read more
For providers
May 14, 2025
10 min read

Unpacking Asian American Eating Disorders and Cultural Influences

Read more
Joel Jahraus
Text Link
For providers

Everybody deserves a full life

Recovery is possible for everyone. We’re here to help you get started.
  • - -
  • Level of care client is interested in

  • By submitting this form, I agree to Monte Nido's Privacy Policy & Terms of Use

  • Should be Empty:
or call
888-228-1253
to speak confidentially with one of our eating disorders specialists to start the road to recovery.
Treatment
  • What we treat
  • Who we serve
  • Our programs
  • Admissions
  • Financial considerations
  • FAQ
  • Our approach
  • Eating disorder quiz
Locations
  • All locations
  • Arizona
  • California
  • Colorado
  • Connecticut
  • Florida
  • Georgia
  • Idaho
  • Illinois
  • Maine
  • Maryland
  • Massachusetts
  • Missouri
  • Montana
  • Nevada
  • New Hampshire
  • New Jersey
  • New York
  • North Carolina
  • Ohio
  • Oregon
  • Pennsylvania
  • Rhode Island
  • South Carolina
  • Tennessee
  • Texas
  • Utah
  • Vermont
  • Virginia
  • Washington
  • Virtual
For You
For loved ones
  • Caring for loved ones
  • Virtual support groups
  • Resources for loved ones
For clients & alumni
  • Post-treatment support
  • Virtual support groups for alumni
  • Request a medical record
  • Resources
for providers
  • Referrals 101
  • Continuing education
  • Meet our Outreach Team
About Us
  • What Monte Nido is
  • Trusted outcomes
  • Leadership
  • Advocacy
  • Testimonials
  • Our work in the news
  • Blog
  • Glossary
  • Careers
Contact Us
  • Reach out to us
  • Request a medical record
Monte Nido logo
Monte Nido Walden LogoMonte Nido Clementine LogoMonte Nido Rosewood Logo
Accredited by Joint Commission, and proud members of the Residential Eating Disorder Consortium and Eating Disorders Coalition
REDC, EDC, APA logos
888-228-1253
© 2024 Monte Nido. All rights reserved.
Accessibility Policy
Data Notification
Privacy Policy
Privacy Practices
Terms and Conditions